Chemotherapy treatment

• US 20030040478A1
• Filed: 07/22/2002
• Published: 02/27/2003
• Est. Priority Date: 12/08/1999
• Status: Abandoned Application

• Current Assignee: 1149336 Ontario Inc.
• Original Assignee: 1149336 Ontario Inc.
• Inventors: Boushey, Robin P, Drucker, Daniel J
• Application Number:
  US10/148,682
• Publication Number:
  US 20030040478A1
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention provides a treatment regimen that is effective in inhibiting chemotherapy-induced apoptosis and promoting cell survival. The invention also relates to a treatment regimen that confers resistance to caspase activation, thereby inhibiting caspase-mediated, proteolytic cleavage of functional cellular enzymes. Specifically, subjects undergoing chemotherapy are first exposed to a pretreatment regimen. Under this regimen, a GLP-2 receptor activator, such as h[GLY2]-GLP2, is administered each day for a predetermined beneficial period, e.g., three consecutive days. Approximately about 1 week following pretreatment, the subjects are exposed to an appropriate chemotherapy treatment regimen. Pretreatment with a GLP-2 receptor activator followed by administration of chemotherapeutic agents improves cell survival, reduces bacteremia, attenuates epithelial injury, and inhibits cellular apoptosis. Moreover, it does not impair the effectiveness of chemotherapy nor result in weight loss. The anti-apoptotic effects of GLP-2 may be useful in the reduction of cytoxicity and bacterial infection induced by chemotherapeutic agents.

Claims

1. A method for treating a subject having a disease or disorder for which treatment by a chemotherapeutic agent is indicated, the method comprising the steps of:

(i) subjecting the subject to a pretreatment regimen effective to alleviate at least one adverse effect of said chemotherapeutic agent, by administering to the subject a GLP-2 receptor activator each day for a predetermined period of time, and

(ii) within about one week following the pretreatment step (i), subjecting the pretreated subject to a treatment regimen involving chemotherapy administration that is appropriate for treating the disease or disorder.

2. The method according to claim 1, wherein the GLP-2 receptor activator is a GLP-2 receptor agonist.

3. The method according to claim 2, wherein the predetermined period of time is from two days to four days.

4. The method according to claim 3, wherein the predetermined period of time is three consecutive days.

5. The method according to claim 4, wherein the GLP-2 receptor agonist is a GLP-2 analog.

6. The method according to claim 5, wherein the GLP-2 receptor agonist is [GLY]hGLP-2.

7. The method according to claim 2, wherein the GLP-2 receptor agonist is administered to the subject twice a day for three consecutive days.

8. The method according to claim 7, wherein the pretreated subject is subjected to a chemotherapy treatment regimen within about 48 hours following said pretreatment step.

9. The method according to claim 4, wherein the chemotherapeutic agent is selected from 5-Fluorouracil and irinotecan.

10. The method according to claim 9, wherein the GLP-2 receptor agonist is a GLP-2 analog.

11. The method according to claim 10, wherein the GLP-2 receptor agonist is [Gly2]hGLP-2.

12. The method according to claim 4, wherein the pretreatment step is performed using a GLP-2 receptor activator as the sole pretreatment agent.

13. The method according to claim 12, wherein the GLP-2 receptor agonist is a GLP-2 analog.

14. The method according to claim 13, wherein the GLP-2 receptor agonist is [Gly2]hGLP-2.

15. The use of a GLP-2 receptor activator for the pretreatment of a subject having a disease or disorder for which treatment by a chemotherapeutic agent is indicated.

16. The use of a GLP-2 receptor activator according to claim 15, wherein said pretreatment comprises the step of subjecting the subject to a pretreatment regimen effective to alleviate at least one adverse effect of said chemotherapeutic agent, by administering to the subject a GLP-2 receptor activator each day for a pretreatment period sufficient to inhibit chemotherapy-induced activation of apoptosis.

17. The use of a GLP-2 receptor activator acccording to claim 16, wherein said pretreatment period is about 3 days.

18. The use of a GLP-2 receptor activator for the preparation of a medicament useful in a therapeutic regimen to treat a disease or disorder for which treatment by a chemotherapeutic agent is indicated, the therapeutic regimen comprising the steps of:

(i) subjecting the subject to a pretreatment regimen effective to alleviate at least one adverse effect of said chemotherapeutic agent, by administering to the subject a GLP-2 receptor activator each day for a predetermined period of time, and

(ii) within about one week following the pretreatment step (i), subjecting the pretreated subject to a treatment regimen involving chemotherapy administration that is appropriate for treating the disease or disorder.

19. The use of a GLP-2 receptor activator according to claim 18, wherein the GLP-2 receptor activator is administered for a pretreatment period of about three days, and the chemotherapy commences within about one week of said pretreatment.

20. The use of a GLP-2 receptor activator according to claim 19, wherein said GLP-2 receptor activator is a GLP-2 receptor agonist.

21. The use of a GLP-2 receptor activator according to claim 20, wherein said GLP-2 receptor agonist is [Gly2]hGLP-2.